Nanoparticles engineered with rituximab and loaded with Nutlin-3 show promising therapeutic activity in B-leukemic xenografts
Clinical Cancer Research (2013) - Comment
pubmed: 23719263  doi: 10.1158/1078-0432.ccr-13-0015  issn: 1078-0432  issn: 1557-3265 

Rebecca Voltan, Paola Secchiero, Barbara Ruozi, Flavio Forni, Chiara Agostinis, Lorenzo Caruso, Maria Angela Vandelli, Giorgio Zauli